Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Inclusion Criteria: * Malignant Disease * Chronic myleogenous leukemia in chronic or accelerated phase * Acute lymphoblastic leukemia (ALL) * First remission high-risk ALL (Ph+, t( 4-11) infants). * Second remission ALL, after a short first remission (\<36 mos from Dx). * 3rd or greater remission ALL. * Acute myelogenous leukemia (AML) * First remission high risk acute nonlymphoblastic (ANLL) (as defined by cytogenetics), if a matched sibling donor is available. * Initial partial remission AML (\<20% blasts in the bone marrow). * AML that is refractory to two cycles of induction therapy. * Second or greater remission AML * Myelodysplastic/Myeloproliferative Disease * Juvenile Myelomonocytic Leukemia (JMML) * Myelosplastic syndrome and/or pre-leukemia at any stage * Lymphoma * Relapsed lymphoma with residual disease that appears to be chemo-sensitive and non-bulky (\<5 cm at largest diameter) * Venous Access: Three lumens of central vascular access will be required for all patients entered on protocol due to the need for a dedicated line for continuous infusion cyclosporine. * Informed Consent: The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained in accordance with the institutional policies approved by the U.S. Department of Health and Human Services. * Patient organ function requirements: * Adequate renal function: Serum Crea…